(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 2.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Phibro Animal Health's revenue in 2026 is $1,500,043,000.On average, 7 Wall Street analysts forecast PAHC's revenue for 2026 to be $61,982,886,048, with the lowest PAHC revenue forecast at $58,778,273,484, and the highest PAHC revenue forecast at $64,376,204,292. On average, 7 Wall Street analysts forecast PAHC's revenue for 2027 to be $64,051,686,564, with the lowest PAHC revenue forecast at $60,968,768,148, and the highest PAHC revenue forecast at $66,282,745,944.
In 2028, PAHC is forecast to generate $66,161,051,796 in revenue, with the lowest revenue forecast at $62,956,439,232 and the highest revenue forecast at $68,919,452,484.